Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Latanoprost effectively ameliorates glucose and lipid disorders in db/db and ob/ob mice.

Wang G, Xu X, Yao X, Zhu Z, Yu L, Chen L, Chen J, Shen X.

Diabetologia. 2013 Dec;56(12):2702-12. doi: 10.1007/s00125-013-3032-8. Epub 2013 Aug 29.

PMID:
23989723
2.

Low molecular weight fucoidan improves endoplasmic reticulum stress-reduced insulin sensitivity through AMP-activated protein kinase activation in L6 myotubes and restores lipid homeostasis in a mouse model of type 2 diabetes.

Jeong YT, Kim YD, Jung YM, Park DC, Lee DS, Ku SK, Li X, Lu Y, Chao GH, Kim KJ, Lee JY, Baek MC, Kang W, Hwang SL, Chang HW.

Mol Pharmacol. 2013 Jul;84(1):147-57. doi: 10.1124/mol.113.085100. Epub 2013 May 8.

3.

Pharmacological profile of a novel, non-TZD PPARgamma agonist.

Chen X, Osborne MC, Rybczynski PJ, Zeck R, Yang M, Xu J, Zhou L, Cryan E, Tang Y, Demarest KT.

Diabetes Obes Metab. 2005 Sep;7(5):536-46.

PMID:
16050946
4.

Arctigenin, a natural compound, activates AMP-activated protein kinase via inhibition of mitochondria complex I and ameliorates metabolic disorders in ob/ob mice.

Huang SL, Yu RT, Gong J, Feng Y, Dai YL, Hu F, Hu YH, Tao YD, Leng Y.

Diabetologia. 2012 May;55(5):1469-81. doi: 10.1007/s00125-011-2366-3. Epub 2011 Nov 18.

PMID:
22095235
5.

Gly-Ala-Gly-Val-Gly-Tyr, a novel synthetic peptide, improves glucose transport and exerts beneficial lipid metabolic effects in 3T3-L1 adipoctyes.

Kim ED, Kim E, Lee JH, Hyun CK.

Eur J Pharmacol. 2011 Jan 10;650(1):479-85. doi: 10.1016/j.ejphar.2010.10.006. Epub 2010 Oct 14.

PMID:
20951125
6.

Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.

Bajaj M, Suraamornkul S, Hardies LJ, Glass L, Musi N, DeFronzo RA.

Diabetologia. 2007 Aug;50(8):1723-31. Epub 2007 May 23.

PMID:
17520238
7.

18F9 (4-(3,6-bis (ethoxycarbonyl)-4,5,6,7-tetrahydrothieno (2,3-c) pyridin-2-ylamino)-4-oxobutanoic acid) enhances insulin-mediated glucose uptake in vitro and exhibits antidiabetic activity in vivo in db/db mice.

Anandharajan R, Sayyed SG, Doshi LS, Dixit P, Chandak PG, Dixit AV, Brahma MK, Deshmukh NJ, Gupte R, Damre A, Suthar J, Padigaru M, Sharma SD, Nemmani KV.

Metabolism. 2009 Oct;58(10):1503-16. doi: 10.1016/j.metabol.2009.04.036. Epub 2009 Jul 15.

8.

Aspalathin improves hyperglycemia and glucose intolerance in obese diabetic ob/ob mice.

Son MJ, Minakawa M, Miura Y, Yagasaki K.

Eur J Nutr. 2013 Sep;52(6):1607-19. doi: 10.1007/s00394-012-0466-6. Epub 2012 Dec 13.

PMID:
23238530
9.

Cilostazol ameliorates metabolic abnormalities with suppression of proinflammatory markers in a db/db mouse model of type 2 diabetes via activation of peroxisome proliferator-activated receptor gamma transcription.

Park SY, Shin HK, Lee JH, Kim CD, Lee WS, Rhim BY, Hong KW.

J Pharmacol Exp Ther. 2009 May;329(2):571-9. doi: 10.1124/jpet.108.146456. Epub 2009 Feb 12.

10.

Acute and chronic treatment of ob/ob and db/db mice with AICAR decreases blood glucose concentrations.

Halseth AE, Ensor NJ, White TA, Ross SA, Gulve EA.

Biochem Biophys Res Commun. 2002 Jun 21;294(4):798-805.

PMID:
12061777
11.

Antihyperglycemic effect of equol, a daidzein derivative, in cultured L6 myocytes and ob/ob mice.

Cheong SH, Furuhashi K, Ito K, Nagaoka M, Yonezawa T, Miura Y, Yagasaki K.

Mol Nutr Food Res. 2014 Feb;58(2):267-77. doi: 10.1002/mnfr.201300272. Epub 2013 Sep 3.

PMID:
24039053
12.

Metformin promotes irisin release from murine skeletal muscle independently of AMP-activated protein kinase activation.

Li DJ, Huang F, Lu WJ, Jiang GJ, Deng YP, Shen FM.

Acta Physiol (Oxf). 2015 Mar;213(3):711-21. doi: 10.1111/apha.12421. Epub 2014 Nov 24.

PMID:
25382002
13.

Rhizoma Anemarrhenae extract ameliorates hyperglycemia and insulin resistance via activation of AMP-activated protein kinase in diabetic rodents.

Han J, Yang N, Zhang F, Zhang C, Liang F, Xie W, Chen W.

J Ethnopharmacol. 2015 Aug 22;172:368-76. doi: 10.1016/j.jep.2015.05.016. Epub 2015 Jul 7.

14.
15.

Anti-diabetic effect of amorphastilbol through PPARα/γ dual activation in db/db mice.

Lee W, Ham J, Kwon HC, Kim YK, Kim SN.

Biochem Biophys Res Commun. 2013 Mar 1;432(1):73-9. doi: 10.1016/j.bbrc.2013.01.083. Epub 2013 Jan 29.

PMID:
23376064
16.

Effect of a novel non-thiazolidinedione peroxisome proliferator-activated receptor alpha/gamma agonist on glucose uptake.

Hu X, Feng Y, Liu X, Zhao XF, Yu JH, Yang YS, Sydow-Bäckman M, Hörling J, Zierath JR, Leng Y.

Diabetologia. 2007 May;50(5):1048-57. Epub 2007 Mar 1.

PMID:
17333104
17.

Cilostazol ameliorates systemic insulin resistance in diabetic db/db mice by suppressing chronic inflammation in adipose tissue via modulation of both adipocyte and macrophage functions.

Wada T, Onogi Y, Kimura Y, Nakano T, Fusanobori H, Ishii Y, Sasahara M, Tsuneki H, Sasaoka T.

Eur J Pharmacol. 2013 May 5;707(1-3):120-9. doi: 10.1016/j.ejphar.2013.03.016. Epub 2013 Mar 22.

PMID:
23528355
19.

Effect of Chinese prescription Kangen-karyu on lipid metabolism in type 2 diabetic db/db mice.

Yamabe N, Kim HY, Kang KS, Zhao Q, Matsumoto K, Yokozawa T.

J Ethnopharmacol. 2010 Jun 16;129(3):299-305. doi: 10.1016/j.jep.2010.03.032. Epub 2010 Apr 2.

PMID:
20363309
20.

Blood glucose-lowering nuclear receptor agonists only partially normalize hepatic gene expression in db/db mice.

Loffler M, Bilban M, Reimers M, Waldhäusl W, Stulnig TM.

J Pharmacol Exp Ther. 2006 Feb;316(2):797-804. Epub 2005 Oct 31.

Supplemental Content

Support Center